Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia
(2018) In Annals of Neurology 84(5). p.729-740- Abstract
- OBJECTIVE: To estimate the prevalence of amyloid positivity, defined by positron emission tomography (PET)/cerebrospinal fluid (CSF) biomarkers and/or neuropathological examination, in primary progressive aphasia (PPA) variants. METHODS: We conducted a meta-analysis with individual participant data from 1,251 patients diagnosed with PPA (including logopenic [lvPPA, n = 443], nonfluent [nfvPPA, n = 333], semantic [svPPA, n = 401], and mixed/unclassifiable [n = 74] variants of PPA) from 36 centers, with a measure of amyloid-β pathology (CSF [n = 600], PET [n = 366], and/or autopsy [n = 378]) available. The estimated prevalence of amyloid positivity according to PPA variant, age, and apolipoprotein E (ApoE) ε4 status was determined using... (More)
- OBJECTIVE: To estimate the prevalence of amyloid positivity, defined by positron emission tomography (PET)/cerebrospinal fluid (CSF) biomarkers and/or neuropathological examination, in primary progressive aphasia (PPA) variants. METHODS: We conducted a meta-analysis with individual participant data from 1,251 patients diagnosed with PPA (including logopenic [lvPPA, n = 443], nonfluent [nfvPPA, n = 333], semantic [svPPA, n = 401], and mixed/unclassifiable [n = 74] variants of PPA) from 36 centers, with a measure of amyloid-β pathology (CSF [n = 600], PET [n = 366], and/or autopsy [n = 378]) available. The estimated prevalence of amyloid positivity according to PPA variant, age, and apolipoprotein E (ApoE) ε4 status was determined using generalized estimating equation models. RESULTS: Amyloid-β positivity was more prevalent in lvPPA (86%) than in nfvPPA (20%) or svPPA (16%; p (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/fdec4fe3-bc37-4bcf-8c66-9fe4a26c81de
- author
- Bergeron, David ; Mattsson, Niklas LU ; Nilsson, Christer LU ; Hansson, Oskar LU and Ossenkoppele, Rik LU
- author collaboration
- organization
- publishing date
- 2018
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of Neurology
- volume
- 84
- issue
- 5
- pages
- 12 pages
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:30255971
- scopus:85056802535
- ISSN
- 1531-8249
- DOI
- 10.1002/ana.25333
- language
- English
- LU publication?
- yes
- additional info
- Export Date: 27 November 2018
- id
- fdec4fe3-bc37-4bcf-8c66-9fe4a26c81de
- date added to LUP
- 2018-11-27 14:59:36
- date last changed
- 2023-12-17 03:55:27
@article{fdec4fe3-bc37-4bcf-8c66-9fe4a26c81de, abstract = {{OBJECTIVE: To estimate the prevalence of amyloid positivity, defined by positron emission tomography (PET)/cerebrospinal fluid (CSF) biomarkers and/or neuropathological examination, in primary progressive aphasia (PPA) variants. METHODS: We conducted a meta-analysis with individual participant data from 1,251 patients diagnosed with PPA (including logopenic [lvPPA, n = 443], nonfluent [nfvPPA, n = 333], semantic [svPPA, n = 401], and mixed/unclassifiable [n = 74] variants of PPA) from 36 centers, with a measure of amyloid-β pathology (CSF [n = 600], PET [n = 366], and/or autopsy [n = 378]) available. The estimated prevalence of amyloid positivity according to PPA variant, age, and apolipoprotein E (ApoE) ε4 status was determined using generalized estimating equation models. RESULTS: Amyloid-β positivity was more prevalent in lvPPA (86%) than in nfvPPA (20%) or svPPA (16%; p}}, author = {{Bergeron, David and Mattsson, Niklas and Nilsson, Christer and Hansson, Oskar and Ossenkoppele, Rik}}, issn = {{1531-8249}}, language = {{eng}}, number = {{5}}, pages = {{729--740}}, publisher = {{John Wiley & Sons Inc.}}, series = {{Annals of Neurology}}, title = {{Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia}}, url = {{http://dx.doi.org/10.1002/ana.25333}}, doi = {{10.1002/ana.25333}}, volume = {{84}}, year = {{2018}}, }